Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009983 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01009983 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants.
The verdict
NCT01009983, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Other find tumor cells and help kill them or carry tumor-killing substances to them. Giving panitumumab together with paclitaxel and carboplatin may be a better way to block tumor growth. PURPOSE: This phase II trial is studying the side effects and how well paclitaxel and carboplatin together with panitumumab works in treating patients with metastatic triple negative breast cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- PROCEDURE laboratory biomarker analysis
- PROCEDURE immunohistochemistry staining method
- BIOLOGICAL panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009983
The ClinicalTrials.gov registry entry for NCT01009983 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT01009983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009983 about?
NCT01009983 is a clinical study titled "Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the abi...
What is the current status of trial NCT01009983?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-03. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01009983?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), laboratory biomarker analysis (PROCEDURE), immunohistochemistry staining method (PROCEDURE), panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01009983?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.